Roots Analysis announced the addition of “Novel Drugs and Smart Devices for Respiratory Disorders, 2018-2030” report to its list of offerings.
Rohit Kumar, the principal analyst, stated, “The continuous investment in this domain has led to the approval of several therapies, such as LAMA / LABA fixed dose combinations, ICS / LAMA / LABA fixed combinations, CFTR modulators, and novel biologics and antibiotics, which have helped improve the quality of life of patients.”
The report presents opinions on several key aspects of the market. Among other elements, it includes:
Kumar further added, “The industry is gradually transitioning towards the development of more targeted therapies. This shift is facilitating a scenario, wherein therapeutic strategies are changing from broad spectrum remedies to those that target individual patient segments.”
The research covers detailed profiles and assesses product portfolios of the following companies:
For additional details, please visit https://www.rootsanalysis.com/reports/view_document/novel-drugs-and-smart-devices-for-respiratory-disorders-2018-2030-/188 or email sales@rootsanalysis.com
Contact:
Gaurav Chaudhary
Tel: +1-604-595-4954
Email: gaurav.chaudhary@rootsanalysis.com
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry
SUBSCRIBE TO INDUSTRY UPDATES